Nf1 gene inactivation in acute myeloid leukemia cells confers cytarabine resistance through MAPK and mTOR pathways
Tóm tắt
Từ khóa
Tài liệu tham khảo
Cros E, Jordheim L, Dumontet C, Galmarini CM . Problems related to resistance to cytarabine in acute myeloid leukemia. Leuk Lymphoma 2004; 45: 1123–1132.
Emanuel PD . Juvenile myelomonocytic leukemia. Curr Hematol Rep 2004; 3: 203–209.
Largaespada DA, Shaughnessy Jr JD, Jenkins NA, Copeland NG . Retroviral integration at the Evi-2 locus in BXH-2 myeloid leukemia cell lines disrupts Nf1 expression without changes in steady-state Ras-GTP levels. J Virol 1995; 69: 5095–5102.
Largaespada DA, Brannan CI, Jenkins NA, Copeland NG . Nf1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia. Nat Genet 1996; 12: 137–143.
Lu D, Nounou R, Beran M, Estey E, Manshouri T, Kantarjian H et al. The prognostic significance of bone marrow levels of neurofibromatosis-1 protein and ras oncogene mutations in patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer 2003; 97: 441–449.
Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004; 428: 332–337.
Johannessen CM, Reczek EE, James MF, Brems H, Legius E, Cichowski K . The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci USA 2005; 102: 8573–8578.
Milella M, Kornblau SM, Andreeff M . The mitogen-activated protein kinase signaling module as a therapeutic target in hematologic malignancies. Rev Clin Exp Hematol 2003; 7: 160–190.